Entrada Therapeutics, Inc. - Common Stock (TRDA)

CUSIP: 29384C108

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 7 signals
Share change
-652,891
Put/Call ratio
0%
SEC-reported price per share
$6.72
Indexed holders
105
Value change
-$4,881,409
Number of buys
66
Open additional details 1 more signal available
Number of sells
48
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
39,243,586

Security key

29384C108

Report period

Q2 2025

Indexed institutions

105

Top holders

10

Ownership snapshot

Top reported holders of TRDA - Entrada Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ROCHE FINANCE LTD
Disclosed value leader
ROCHE HOLDING LTD
Comparable rows
3/15
Latest evidence
31 Mar 2025
13D/G 13F 3/4/5 Lead comparable stake: 6.9% 12 rows are not safely comparable across share classes. 13D/G row: ROCHE FINANCE LTD Showing 1-6 of 15 holder rows.

Quick read

ROCHE FINANCE LTD leads the comparable SEC ownership view at 6.9%.

3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ROCHE FINANCE LTD's linked filing trail.
Comparable ownership Top 3
ROCHE FINANCE LTD 6.9%
BlackRock, Inc. 5.3%
Janus Henderson Group Ltd. 4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ROCHE FINANCE LTD
13D/G
6.9%
Reported 13D/G · 31 Dec 2024
$23,019,270
2,569,115 shares
$0 31 Dec 2024
BlackRock, Inc.
13F 13D/G
Company
5.3%
Reported 13D/G · 31 Dec 2024
$17,997,312
1,990,853 shares
— 31 Mar 2025
Janus Henderson Group Ltd.
13F 13D/G
Company · JANUS HENDERSON GROUP PLC
4%
Reported 13D/G · 30 Jun 2025
$20,304,229
2,121,654 shares
— 31 Mar 2025
ROCHE HOLDING LTD
3/4/5
10%+ Owner
—
denominator unverified
$44,988,265
2,813,525 shares
— 02 Nov 2021
Redmile Group, LLC
3/4/5
10%+ Owner
—
denominator unverified
$31,251,176
1,954,420 shares
— 02 Nov 2021
BAKER BROS. ADVISORS LP
13F
Company
13F
—
denominator unverified
$43,987,004
4,865,819 shares
— 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
105
Shares
29,583,750
Indexed holders
105
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 indexed holders
110
Q2 2025 indexed holders
105
Indexed holder difference
-5
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .